Antibody engineers continue to push the boundaries of antibody technology, designing an ever-increasing number of unique antibody formats to generate next-generation therapeutics, improve diagnostic assays, and drive scientific research forward. This talk will present several recent advances in the application of antibody engineering across research and diagnostics, including species-matched and effector function-tailored antibodies for improved in vivo research, recombinant isotype panels for standardization of serological assays, multivalent fragment constructs for higher avidity diagnostic assays, and recent research comparing characteristics of different bispecific antibody formats.
Improving Antibody Function with Antibody Sequencing and Characterization
Characterizing engineered antibodies is crucial in their development for therapeutic and diagnostic purposes. The engineering process involves modifying antibody formats, which consequently changes antibody properties such as affinity, and stability. To address this, characterizing antibody properties such as protein sequence, epitopes, binding kinetics, and glycan profile becomes essential. Bispecific antibodies can be optimized with kinetic analysis by surface plasmon resonance (SPR) and epitope mapping by hydrogen-deuterium exchange mass spectrometry (HDX-MS). This information allows for rational engineering, ensuring the preservation and enhancement of desired properties in the engineered antibodies, ultimately optimizing their effectiveness and utility in various applications.